Purpose of review Management of coagulation in neurosurgical procedures is challenging. In this contest, it is imperative to avoid further intracranial bleeding. Perioperative bleeding can be associated with a number of factors, including anticoagulant drugs and coagulation status but is also linked to the characteristic and the site of the intracranial disorder. The aim of this review will be to focus primarily on the new evidence regarding the management of coagulation in patients undergoing craniotomy for neurosurgical procedures.
INTRODUCTION
Coagulopathy in brain injured patients is common, and it is frequently associated with increased patient morbidity and mortality [1] .
It is paramount to avoid further progression of intracranial hemorrhage in neurosurgical patients who have sustained brain injury. Perioperative bleeding can be associated with a number of factors, including anticoagulant drugs and deranged coagulation status, but is also linked to the characteristic and the site of the intracranial injury (trauma, tumor and hematoma).
Blood transfusions and blood component therapy can be lifesaving in life-threatening hemorrhage, but they could also result in several potential complications. However, strong evidence proving a connection between coagulopathy and mortality, as well as an optimal transfusion practice to adopt in this group of patients, is lacking.
A recent systematic review confirmed the overall poor quality of research studies in coagulopathy in trauma patients [2] . Only the use of tranexamic acid seems to be effective in reducing mortality in trauma, but not yet in traumatic brain injury (TBI) [2] . The role of other transfusion practices, including the fixed blood to plasma transfusion ratio and hypofibrinogenemia treatment, has not been adequately studied in literature. Coagulopathy in TBI is very common, even if not significantly higher when compared with similarly severe injuries to other areas of the body, or with multiple injuries associated with TBI.
Moreover, the occurrence of coagulopathy in TBI enhances the progression of traumatic hemorragic injuries yielding finally to a poorer prognosis and outcome [1] .
Coagulation disturbances and thrombocyte dysfunctions are risk factors not only in the emergency settings, but also for many other neurosurgical conditions, including chronic subdural hematoma and elective neurosurgery. This dilemma becomes even more significant as the number of patients prescribed with anticoagulation or antiplatelet drugs rise, the various types of these drugs increases and their prescription. The aim of this review will primarily focus on the new evidence regarding the coagulation management in patients undergoing craniotomy for neurosurgical procedures.
GENERAL CONSIDERATIONS
Perioperative bleeding can be associated with a number of factors, including antihemostatic and anticoagulant drugs [3] . On the other hand, there is also an increased risk of venous thromboembolism after elective and emergency neurosurgery, and hypercoagulative state has been described in several patients, in particular after brain tumor surgery [4] . To balance thrombosis risk versus bleeding hazard, it is important to know what changes in coagulation occur in the perioperative period. Routine coagulation tests include activated partial thromboplastin time (aPTT), prothrombin time (PT), platelet count and fibrinogen levels. Additional parameters that can be useful are measurements of activated coagulation and fibrinolysis (e.g. thrombinantithrombin complex and plasmin-a 2-antiplasmin complex). Moreover, newly introduced viscoelastic instruments, such as thromboelastography (TEG) and rotational thromboelastometry are becoming point-of-care tools, helpful for quickly assessing global hemostatic function in whole blood and for guiding the correct treatment for bleeding.
INTRACRANIAL BLEEDING
Patients receiving anticoagulation therapy who present with any type of intracranial hemorrhage -including subdural hematoma, epidural hematoma, subarachnoid hemorrhage and intracerebral hemorrhage (ICH) -require urgent correction of their coagulopathy to prevent hemorrhage expansion, limit tissue damage and facilitate surgical intervention as necessary.
VITAMIN K ANTAGONIST
Warfarin is the most widely used oral anticoagulant. Reversal of vitamin K antagonists is based on immediate anticoagulant discontinuation, and vitamin K administration (10 mg intravenously over 30 min) with international normalized ratio monitoring. Reversal of anticoagulation and repletion of deficient coagulation factors by means of fresh frozen plasma transfusion or prothrombin concentrate complex (PCC). Recombinant activated factor VII is not recommended for its prothrombotic rebound effect [5] .
DIRECT ORAL ANTICOAGULANTS
Direct oral anticoagulants (DOACs), are a newer class of antiocoagulants, which do not require monitoring, have a wider therapeutical range and a safer pharmacological profile. This drug class includes the direct thrombin inhibitor dabigatran and the direct factor Xa inhibitors rivaroxaban, apixaban and edoxaban.
Compared with warfarin, DOACs have a shorter half-life, averaging around 12 h, and an onset time
KEY POINTS
Despite extensive research in the past, mechanisms for the initiation and propagation of coagulopathy in patients with TBI remain poorly understood; only the use of tranexamic acid seems to be effective in reducing mortality in trauma, but not yet in TBI.
New oral anticoagulants are increasingly prescribed, these direct thrombin inhibitors have been reported to have a similar or lower intracranial bleeding risk as compared with warfarin; however, there are no quickly available tests for assessing the degree of anticoagulation nor is there a readily available reversal strategy.
The use of viscoelastic instruments such as thromboelastography and rotational thromboelastometry have been proposed as predictors of the risk of progression of intracranial hemorrage in patients with TBI; one of the greatest clinical benefits of this technology is in the definition of the coagulopathy to factor, platelet or fibrinogen deficiencies.
Postoperative venous thromboembolism is a serious surgical complication and most often it results in increased morbility and mortality; appropriate and detailed information on both patient-bound factors (malignancy, subarachnoid hemorrhage, preexisting coagulopathies) and treatment-associated risk factors (type of surgery, length of surgery, postoperative immobilization) is needed to assess optimal antithrombotic prophylaxis for neurosurgical patients. between 1 and 4 h. In case of intracranial bleeding, first obvious main stand of all DOACs-related coagulopathy is the discontinuation of the drug; second, if the drug intake dates back up to 2 h, activated charcoal (50 g) administration is recommended. In case of dabigatran (direct thrombin inhibitor), quick reversal of the anticoagulation is now possible by mean of a specific and newly introduced mAb fragment named idarucizumab (5-g intravenous (IV) divided in two doses). Whenever idarucizumab is not available, current evidence recommends the use of activated PCC or four-factor PCC (50 U/kg). As dabigatran is poorly bound to plasma protein, hemodialysis is another potential and effective tool for removing the drug from the circulation, although more cumbersome especially in emergency settings [5] .
In a recent article [6] studying the clinical and radiological course of intracranial hemorrage in patients on novel oral anticoagulants, vitamin K antagonists, platelet inhibitors and patients without anticoagulant/antiplatelet drugs, the authors observed mortality and hemorragic complications proved to be as high as in patients with other oral anticoagulant/antiplatelet drugs. This despite the fact that the clinical outcome in patients with intracranial hemorrage and taking new anticoagulants is overall poor (Figure 1 ).
UNFRACTIONED HEPARIN
Reversing anticoagulation in patients when intracranial hemorrhage develops during full-dose heparin infusion is mandatory; instead, counteraction of prophylactic heparin is not indicated unless aPTT is significantly prolonged (Good Practice statement). Unfractioned heparin (UHF) pharmacological activity reversal is obtained through administration of IV protamine sulfate at 1 mg for every 100 U of heparin given in the previous 2-3 h with a maximum single dose of 50 mg (strong recommendation, moderate-quality evidence). If the aPTT remains elevated, a second administration of protamine at a dose of 0.5-mg protamine per 100 U of unfractionated heparin is suggested [5] .
LMWH
Guidelines recommend discontinuing low molecular weight heparin (LMWH) when intracranial hemorrhage is present or suspected (Good Practice statement); reversing LMWH in patients with intracranial hemorrhage receiving therapeutic doses of LMWH (strong recommendation, moderate evidence) and finally, protamine administration by slow IV injection over a period of about 10 min.
ANTIPLATELET AGENTS
The current antiplatelet medications are acetilsalcylic acid (ASA), dipyridamole, ticlopidine, clopidogrel and the newest, prasugrel.
When intracranial hemorrhage is diagnosed or suspected, discontinuing antiplatelet agents is recommended. Platelet transfusion is suggested for patients with aspirin or ADP inhibitor-associated FIGURE 1. Pragmatic step-wise approach to direct oral anticoagulant-treated patients suffering from trauma [22] . www.co-anesthesiology.comintracranial hemorrhage who will undergo a neurosurgical procedure (conditional recommendation, moderate-quality of evidence) [5] .
DEEP VENOUS THROMBOSIS PROFILAXIS
It has been demonstrated that patients undergoing neurosurgical cranial procedures are significantly more likely to suffer venous thromboembolism (VTE) than those undergoing spinal procedures. Moreover, those who receive craniotomy for brain tumor, especially glioma (15%) and meningioma (7.1%), show the highest incidence of deep venous thrombosis (DVT) and makes them more vulnerable for pulmonary thromboembolism [7, 8] .
DVT and pulmonary thromboembolism prophyaxis is achieved through prevention of venous stasis in the lower limbs by applying intermittent pneumatic compression (IPC) devices or compression stockings and through the use of LMWH or UHF at a prophylactic dosage.
SPECIFIC CONSIDERATIONS

Elective craniotomy
For patients undergoing elective craniotomy, current guidelines recommend initiation of DVT prophylaxis by using IPC with either LMWH or UFH within 24 h after craniotomy (strong recommendation and moderate-quality evidence) [9] .
In a recent meta-analysis, Alshehri et al.
[10] compared 10 different randomized clinical trials to assess safety and efficacy of DVT prophylaxis among patients with brain tumors undergoing craniotomy. In terms of efficacy, their meta-analysis demonstrated that prophylaxis actually reduced the incidence of venous thromboembolism, specifically UHF alone showed a stronger VTE reduction risk (RR) compared with placebo [RR ¼ 0.27; 95% confidence interval (CI): 0.10-0.73], whereas LWMH combined with mechanical prophylaxis performed better than mechanical prophylaxis alone (RR ¼ 0.61; 95% CI: 0.46-0.82) on VTE reduction.
Severe traumatic brain injury
Among trauma patients admitted to hospital, pulmonary thromboembolism is the third leading cause of death in those surviving the first 24 h (Figure 2 ) [11] .
Paucity of randomized, controlled and adequately powered clinical trials characterize the available literature regarding DVT prophylaxis in TBI. Byrne et al. conducted a propensity-matched cohort study with the purpose of identifying the optimal timing of pharmacologic VTE prophylaxis initiation in severe TBI patients. These authors compared two cohorts of severe TBI patients, one receiving early pharmacological prophylaxis (within 72 h from hospital admission) and the other receiving late pharmacological prophylaxis (after 72 h). They observed that the overall incidence of pulmonary thromboembolism and DVT in both the cohorts was 1.7% and 6.5%, respectively, but patients who received early prophylaxis had significantly lower rates of pulmonary thromboembolism and DVT compared with late prophylaxis patients [12] .
Intracerebral hemorrhage
Regarding patients with ICH, Neurocritical Care Society 2016 Guidelines recommend the use of IPC and/or compression stockings for VTE prophylaxis over no prophylaxis starting at the time of hospital admission (strong recommendation and high-quality evidence). They also suggest the initiation of prophylactic doses of subcutaneous UFH or LMWH to prevent VTE in patients with stable hematomas and no ongoing coagulopathy beginning within 48 h of hospital admission (weak recommendation and low-quality evidence) [9] .
Ischemic stroke
In the context of VTE prevention in ischemic stroke, literature provides a good number of sufficiently powered trials and meta-analysis supporting the use of both pharmacological and concurrent mechanical prophylaxis with IPC devices. As long as elective or emergent craniotomy is concerned in this category of patients, literature states that both UFH and LMWH are well tolerated for VTE prophylaxis [9] .
Subarachnoid hemorrhage
Patients affected with aneurysmal subarachnoid hemorrhage (aSAH) are at increased risk of developing VTE. The incidence of lower limbs DVT ranges from 1.5 to 24% and the incidence of clinically evident pulmonary embolism is 1.2-2.0% [13] . According to the current evidence, the Neurocritical Care Society recommends VTE prophylaxis with UFH in all patients with aSAH (strong recommendation and high-quality evidence) except in those with unsecured ruptured aneurysms expected to undergo surgery (strong recommendation and low-quality evidence). Guidelines recommend initiation of IPCs as VTE prophylaxis as soon as patients with aSAH are admitted to the hospital (strong recommendation and moderate-quality evidence) and VTE prophylaxis with UFH at least 24 h after the aneurysm has been secured by surgical approach or by coiling (strong recommendation and moderate-quality evidence) [9] .
New frontiers in genetic and biomolecular studies
Several markers have been proposed in the diagnosis and treatment of stroke, especially their role in the differential diagnosis of hemorrhagic and ischemic incidents.
In a recent study, the concentration of intracellular adhesion molecule-1 (ICAM-1) and vascular cell adhesion molecule-1 (VCAM-1) as well as coagulation factors in the blood of 85 patients in the early phase following subarachnoid hemorrhage was evaluated to assess their utility as diagnostic markers of clinical severity [14] . These authors found that the concentration of ICAM-1 and VCAM-1 was significantly higher in patients after subarachnoid hemorrhage; moreover they also observed a higher concentration of fibrinogen, a shorter aPTT and a higher concentration of D-dimers in patients with poor neurological status at presentation. A recent meta-analysis [15] evaluated the association between the Val34Leu polymorphism in blood coagulation factor XIII-A in patients with intracerebral hemorrhage and found that blood coagulation factor XIII (FXIII) is the last enzyme affecting the final stages of the coagulation cascade, therefore playing a vital role in endothelial homeostasis in the brain. Furthermore, homozygous FXIII deficiency was correlated with a 25-60% risk of intracranial hemorrhage, and FXIII-A Val34Leu polymorphism was associated with intracranial hemorrhage susceptibility, although no significant association between the FXIII-A Val34Leu polymorphism and risk of intracranial hemorrhage in the overall population was demonstrated.
In the field of brain trauma, several genetic studies have been proposed as well. Among these, Hopp et al. [15] investigated the impact of genetic deficiency of factor XII and acute inhibition of activated factor XII in an experimental animal model of trauma-induced microvascular thrombus. As thrombus formation in the cerebral microcirculation can contribute to secondary brain damage by causing pericontusional ischemia, the authors aimed to obtain preclinical evidence supporting the hypothesis that targeting factor XII may prevent thrombus formation and produce beneficial effect on outcome after TBI. According to their results, both genetic deficiency of factor XII and inhibition of activated factor XII in mice can reduce traumainduced microvascular thrombus formation and improve outcome, whilst administration of human factor XII in factor XII-deficient mice fully restored injury-induced microvascular thrombus formation and the related brain damage. These findings suggest a possible novel treatment option that can decrease the ischemic burden after TBI without increasing the risk of bleeding.
In another recent experimental study, protease activated receptor 1 (PAR-1), which is the most abundant thrombin-activated receptor in the central nervous system and thrombin changes related to TBI, were investigated. It is known that minimal TBI is associated with microscopic bleeds and consequent activation of coagulation factors and with immediate releases of thrombin-like activity in the brain probably mediated by the activation of PAR-1. Through N-Methyl-D-aspartic acid activation, glutamate release and loss of long-term potentiation, PAR-1 can induce amnesia [16] . In this model, thrombin activity increased initially and returned to baseline 1 h following the trauma and increased again after 72 h. These changes were associated with a significant increase in PAR-1 levels at 24 and 72 h following the trauma. Therefore, these results show a late rise in thrombin activity following TBI, which is directly implicated in activation of PAR-1. The early transient rise in thrombin activity is expected as trauma damages blood vessels, resulting in microscopic bleeds.
The role of thromboelastogram in neurosurgery
The TEG provides information regarding the hemostatic function in whole blood rather than measurements of single components of the clotting process such as PT, aPTT or platelet count. It also provides a graphical representation of the mechanism of clot formation assessed by the degree of traction on a pin suspended in a spinning cup of blood. TEG has been extensively used in cardiosurgery, though recently it has been proposed as a predictor of the risk of progression of intracranial bleed in patients with TBI [17] [18] [19] . As many patients with intracranial hemorrhage progression show normal coagulation values, some authors hypothesized that TEG could have a role in the prediction of the progression of intracranial hemorrhage and mortality. By analyzing a cohort of 169 patients, these authors found no differences in mortality or TEG values in patients who developed progression of intracranial hemorrhage, they thus concluded that caution is needed against relying on TEG to guide clinical decisions related to intracranial hemorrhage progression [20] .
On the other hand, some authors found that TEG values are associated with poor outcome in SAH patients and may identify the well described platelet-mediated hypercoagulable state [21] . In particular, they found that the association between maximal amplitude, a marker of platelet function and outcome was even stronger than traditional coagulation and inflammatory markers (D-dimer and fibrinogen,), suggesting that maximal amplitude, independent of age and Hunt Hess grade, is a more robust predictor of functional outcome than these other markers. Finally, the use of TEG has been recently proposed to monitor coagulation state and fluid replacement in elective surgical procedures in patients undergoing neurosurgery with craniotomy for brain tumor resection [22] .
CONCLUSION
Coagulation management remains a major issue in patients undergoing neurosurgical procedures.
Trauma-induced coagulopathy as well as the use of anticoagulants can determinate progressive hemorrhagic injury which is demonstrated to be associated with a high risk of poor outcome. Currently, literature does not provide strong evidence regarding the hazards associated with the use of new anticoagulants. Close monitoring and quick reversal of coagulopathy may improve the outcome in this group of patients. However, overall quality of the reported literature is poor, and therefore further studies are necessary to identify optimal management strategies.
